For the TakeAim CLL study, Curis said the number of consented patients has risen to 10, up from six announced on July 6, 2026. (Streetinsider.com) - Jul 22, 2026 - "The company said it expects to dose the first five patients by the end of July. Curis also raised its year-end data guidance to 5–10 patients in December 2026, up from a prior guidance of five patients....The TakeAim CLL study is an open-label Phase 2 trial evaluating emavusertib combined with zanubrutinib in CLL patients who have measurable residual disease after at least 12 months on zanubrutinib."
Enrollment status • P2 data • Chronic Lymphocytic Leukemia
|